We performed a retrospective single center study to define the epidemiology of bacteremias or invasive mycoses in pediatric allogeneic hematopoietic SCT (HSCT) from matched related donors (MRD) or alternative donors (AD). During 119 213 days of follow-up, 156 infections were observed: 130 bacteremias (27 in MRD-HSCT and 103 in AD-HSCT recipients) and 26 invasive mycoses (8 in MRD-HSCT and 18 in AD-HSCT recipients). Overall, the risk of bacteremia was fivefold that of invasive mycosis (Po0.001). AD-HSCT recipients had a higher percentage of infections (89 vs 27%; Po0.001), a higher rate/100 days of immunosuppression (infection rate (IR): 0.21 vs 0.06; Po0.001) and a higher proportion of repeated infections (44 vs 9%; P ¼ 0.001). In AD-HSCT, the relative risk of bacteremia was 2.87 in the pre-engraftment period, 5.84 in the early post-engraftment period and 6.46 in the late post-engraftment period (Po0.001) compared to MRD-HSCT. Only after 1 year did the epidemiology become similar. The epidemiology of invasive mycoses did not differ significantly between the two types of transplant.
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Background
Bacteremias and invasive fungal infections (IFI) represent severe complications after allogeneic hematopoietic SCT (HSCT). Even if the majority of febrile episodes are classified as fever of unknown origin, bacteremias and invasive mycoses are generally used as surrogate markers of the infection burden when deciding management strategies. It is thus important to have information on their epidemiology during the different post transplant phases. In general, it is well known that incidence of infectious complications varies in the different post transplant periods (pre-engraftment, early post-engraftment or late post-engraftment) 1 and depends on type of donor (familiar or non-familiar) and the degree of HLA matching (full or partial). 2 Mucositis, neutropenia, age at transplant, presence of indwelling central venous catheters (CVC), acute or chronic GvHD and drugs administered for its management represent other well-known risk factors for infectious complications. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] However, in any single patient, it is difficult to disentangle the role of risk factors that may be present either contemporarily or subsequently at any time after HSCT. In this study, we thus adopted a pragmatic approach to the analysis of infectious complications and decided to evaluate their epidemiology according to the type of donor and the different postallogeneic HSCT periods.
Patients and methods
All consecutive children (0-14 years) treated with allogeneic HSCT at the Gaslini Children Hospital in Italy between January 1987 and December 2004 were eligible for this study. Data on demographics, underlying disease, date and type of transplant, and updated follow-up status and survival were already available in an institutional database for each eligible patient. For the purposes of the present study, patients were further divided into two categories based on their donor type: (a) fully HLA compatible familiar, defined as matched related donor (MRD) and (b) all other types of donor (for example, matched unrelated, familiar not fully matched), defined as alternative donor (AD).
In a separate database, information (that is, etiology, localization and date of diagnosis) was collected on any episode of bacteremia or IFI occurring in transplanted patients. Unfortunately, data on viral infections occurring during most of the study period were not available.
Single-agent bacteremia was defined as the isolation of a single bacterial pathogen from blood culture. For coagulase-negative staphylococci, corynebacteria other than Corynebacterium jeikeium and other skin contaminants, at least two sets of positive blood cultures were required unless the same pathogen was simultaneously isolated from the blood and another site of infection. Polymicrobial bacteremia was defined as the isolation of more than one pathogen from the same blood sample or from two consecutive samples obtained within 24 h. 13 In 2002, after the publication of the EORTC/MSG (European Organization for Research and Treatment of Cancer/Mycoses Study Group) criteria, 14 all the episodes of IFI were retrospectively reviewed and classified by three of the investigators (EC, MF and RH) as proven (isolated fungemia or deep organ infections), probable and possible invasive mycoses. An infectious episode was defined as neutropenia related if documented in presence of an absolute granulocyte count o1.0 Â 10 9 /l 15 and CVC related in presence of at least one of the following conditions: 4, 16 (1) fever (438 1C) with chills and rigors within 1 h after catheter flushing or manipulation; (2) simultaneous quantitative cultures of blood samples with a ratio of 5:1 (CVC vs peripheral); (3) differential time to positivity (that is, a positive result of culture from a CVC obtained at least 2 h earlier than a positive result of culture from peripheral blood); (4) double-lumen CVC: fivefold difference in colony-forming units (CFU)/ml between the two lumens; (5) single-or double-lumen CVC: CVC culture yields X100 CFU/ml. Deaths occurring within 15 days after diagnosis of bacteremia or within 90 days after IFI were defined as infection related.
Standard of care during the study period During the post transplant period and until discharge from the hospital, patients were placed in single rooms with air conditioning and high efficiency particulate air (HEPA) filters. 17 In case of new hospitalization due to the occurrence of complications, patients were admitted to a different unit, with similar characteristics. When outside the wards, patients were recommended to wear face masks with high filtration (HEPA) capability. 18 Maintenance procedures for CVC were always performed according to international recommendations. 19 All patients received prophylaxis for Pneumocystis jiroveci pneumonia starting the second week after HSCT and until the end of immunosuppressive treatment. 13, 20 G-CSF was administered only in selected cases and in particular in neutropenic patients with severe infectious complications (for example, invasive aspergillosis). Primary antibacterial prophylaxis was not routinely administered, while primary antifungal prophylaxis with fluconazole was adopted after 1992. 13 Secondary antifungal prophylaxis was administered to all patients with a diagnosis of IFI before HSCT. The drugs were chosen according to the isolated/more probable pathogen and the clinical picture. 13 Patients with isolated pulmonary lesions also underwent surgical resection of the lesion before HSCT. 21 In case of febrile episodes, blood cultures were usually performed through the CVC, while phlebotomy was performed only in case of suspected CVC-related infection. 22, 23 The combination of a b-lactam and an aminoglycoside or monotherapy with a b-lactam active against Pseudomonas was used as initial empirical antibacterial therapy of fever. 13 Modifications to initial treatment were performed on the basis of bacterial sensitivity or clinical criteria. 13 Empirical antifungal therapy with amphotericin B (deoxycholate or liposomal) was administered after at least 5 days of fever in neutropenic patients. 13 Since 1998, sequential computed tomography scan and detection of the Aspergillus galactomannan antigen were used for early diagnosis of invasive mycoses. 13 The vaccination policy after HSCT was that recommended by the EBMT (European Group for Blood and Marrow Transplantation) Infectious Diseases Working Party. 24 Moreover, since 2003, tetanus-conjugated Streptococcus pneumoniae heptavalent vaccine was introduced in the post transplant infection prophylaxis program. 25 Standard procedures for GvHD prophylaxis and management were based on type of graft. In detail, CYA was given to all allogeneic marrow recipients from day À1 and discontinued after 6-12 months since transplant or at the remission of chronic GvHD. 26 In AD-HSCT recipients, antithymocyte globulin from day À4 to day À2 and low-dose methotrexate at day þ 1, þ 3, þ 6, þ 11 after HSCT were also given. 26 In cases of acute and chronic GvHD, steroids were administered and the schedule was tailored to the patient's clinical condition. In case of unsatisfactory clinical response or of drug-related adverse events, other immunosuppressants (for example, tacrolimus, monoclonal antibodies or extracorporeal photopheresis) were prescribed at the treating physician's judgment.
Because of the retrospective nature of the study, no data were collected on neutropenic periods, presence of mucositis and degree or extent of GvHD; the type of immunosuppressive therapy was coded as with or without steroids, and the absolute number of courses of extracorporeal photopheresis was also evaluated.
Statistical analysis
Period at risk for developing any infectious episode was measured as person-days at risk (pdr) and defined as the interval between the day of transplant and that of discontinuation of any immunosuppressive treatment day þ 1, which could have been due to its elective end, relapse or death, whichever occurred first. If a second transplant was performed, another treatment period was calculated using the same above criteria starting from the date of the second HSCT. Follow-up information was censored at 31 December 2004.
Analysis of possible modification in the epidemiology of infections because of changes in management strategies was carried out considering three periods divided by two milestones, that is introduction of fluconazole prophylaxis (1992) and of computed tomography scan and galactomannan serial testing (1998).
Four 'biologically relevant' periods at risk after HSCT were further defined for analysis: (1) days 0-30 characterized by the presence of pre-engraftment neutropenia and possible development of acute GvHD; (2) days 31-100 when acute GvHD may develop; (3) days 101-365 when chronic GvHD may occur and usually immunosuppression is electively discontinued; and (4) 4365 days when persistent chronic GvHD may be present and thus immunosuppressive treatment continued.
Descriptive statistics were reported as absolute frequencies or percentages for qualitative data and as medians and range for quantitative data. Data were reported overall and considering separately bacteremias and IFI. The overall incidence of infectious episodes was calculated as the percentage of events out of the total number of procedures. The incidence of repeated infections was calculated using as denominator the number of transplants with at least one infectious episode. Comparison of frequency distribution was analyzed by the w test or Fisher exact test, if appropriate. The infection rate (IR) was calculated by dividing the number of events by the pdr and expressed as episodes/100 pdr, with 95% confidence intervals (95% CI) calculated by using tables of the Poisson distribution function. Comparisons among various IR were performed by means of the likelihood ratio test in a Poisson regression model 27 and measured as relative risk (RR) of AD-HSCT recipients as compared to MRD-HSCT recipients. The Kaplan-Meier method was used to calculate the cumulative risk estimates of infections, and only the first infectious episode, if any, was considered for each patient. Differences in the cumulative risks were evaluated by means of the log-rank test. 28 All tests were two-tailed and a P-value p0.05 was considered as statistically significant. The statistical software 'Statistica' (release 6.0, StatSoft Corporation, Tulsa, OK, USA) and the software 'Stata' (release 7.0, StataCorp 2001, College Station, TX, USA) were used.
All the HSCT patients or their guardians had previously signed a consent form allowing the use of their data for clinical research purposes. The procedures we followed were in accordance with our institution ethical standards and with the Declaration of Helsinki Principles. According to Italian guidelines, no other specific informed consent was required for purposes of this study.
Results
During the study period, 267 pediatric allogeneic HSCT were performed at our institution for a total of 119 213 pdr of immunosuppression (Table 1) . In more detail, 131 children (49%) received HSCT from an MRD (total 61 566 pdr) and 136 (51%) from AD (total 57 647 pdr). Overall 107 HSCT (40%) were complicated by at least one infectious episode, and in 36 of these (34%) more than one episode (range 2-4) was documented for a total of 156 infections (130 bacteremias and 26 invasive mycoses) and an overall IR of 0.13 (95% CI 0.07-0.18). The analysis for temporal trends in the epidemiology of infections in the two types of HSCT did not demonstrate any significant change over time (Table 2) . Table 3 reports on the etiology of bacteremias and on etiology, classification and localization of fungal infections. Table 1 further reports on the distribution of different types of infectious episodes according to the type of HSCT. Overall, the IR of bacteremias (0.11) was significantly higher than that of invasive mycoses (0.02), Po0.001. Compared to MRD-HSCT recipients, children receiving AD-HSCT had a significantly higher percentage of infections (89 vs 27%; Po0.001), IR (0.21 vs 0.06; Po0.001) and proportion of HSCT with 41 episode (44 vs 9%; P ¼ 0.001). In contrast, no differences between the two types of HSCT were found regarding the incidence of neutropenia-(P ¼ 0.06) and of CVC-related infections (P ¼ 0.56).
In a further analysis, the incidence of bacteremias and IFI was evaluated considering the four biologically relevant periods at risk (Table 4) . Compared with MRD-HSCT recipients, AD-HSCT children had higher proportions and rates of bacteremias in all the periods after transplant. In both types of HSCT, the rates of bacteremia decreased through the four biologically relevant periods. If the proportion of patients with infection was considered, in MRD-HSCT recipients, it was high (11%) in the first period and then decreased to an almost stable level (that is, between 3 and 5%) in the following ones. In contrast, among AD-HSCT recipients, the proportion of episodes in the 101-365 day period (32%) was as high as that observed in the 0-30 period (30%). Overall, AD-HSCT recipients had a 4.07-fold increased risk of developing bacteremia. This risk was significantly higher during the first year after transplant, with higher values in the post-engraftment periods (days 31-100, RR 5.84; and days 101-365, RR 6.46), while it was still higher (RR 2.6) but not significantly different after day 365 (Table 4) .
The estimated cumulative risk to develop an episode of bacteremia after allogenic HSCT was 44% (95% CI 36-54). In particular, it was 25% after MRD-HSCT (95% CI 16-39) with the last event occurring 26 months after transplant and 65% (95% CI 53-76) after AD-HSCT with the last event occurring 19 months after the procedure (Po0.001).
In the analysis of the epidemiology of the few (n ¼ 26) cases of IFI, the behavior of the two types of HSCT was similar to that observed for bacteremias, but the differences were never significant ( Table 4 ). The overall cumulative risk to develop an IFI was 20% (95% CI 9-40). In particular, it was 11% after MRD-HSCT (95% CI 4-28) with the last event occurring 26 months after transplant and 24% (95%CI 11-48) after AD-HSCT with the last event occurring 54 months since the procedure (P ¼ 0.043). Moreover, no significant difference was observed in the analysis of timing of infections due to yeasts or filamentous fungi, on the development of infection before or after hospital discharge and on the type of previous bacterial infection, if any (data not shown).
Finally, the impact of the type of immunosuppression (with or without steroids) on the IR of bacteremias and invasive mycoses on each type of HSCT was analyzed (Table 5) and no difference was observed in patients receiving the same type of HSCT. Only one episode of bacteremia was observed during the 42 courses of extracorporeal photopheresis.
Discussion
This single center study in which 450% of AD-HSCT and o25% of MRD-HSCT were complicated by an infectious episode demonstrated that in children the donor source is an important risk factor for the development of severe infections, as reported previously in adults. 8, [29] [30] [31] The fact that AD-HSCT recipients have a higher risk is not surprising and is probably due to the more aggressive GvHD prophylaxis (for example, methotrexate, antithymocyte globulin)-the immunosuppression determined by 56 (36) 14 (40) 42 (35) 0.56 Deaths due to bacteremias (% of all episodes)
14 (11) 1 (14) 13 (13) the transplant per se-and the presence, extension and management of GvHD. 2, 11, 32 Since we thought that it had been very difficult to disentangle the effect of any single factor in any specific period after transplant, we decided to adopt a more pragmatic approach to this problem by measuring rates and proportions of infectious complications considering the four biological relevant periods at risk.
In both types of transplant, bacteremias were far more frequent than invasive mycoses (in 49 vs 9% of procedures and IR 0.11 vs 0.02). Both types of infection, however, had a similar behavior over time and in the four biologically relevant post transplant periods identified. The highest burden was observed in the pre-engraftment period when usually neutropenia and mucositis are more severe, 1, 3, 5, 6, [10] [11] [12] 33 whereas it decreased in the following ones, even if it was still present in a non-negligible proportion of patients. This fact further confirms that also pediatric allogeneic HSCT recipients, and in particular those engrafted by an AD, are at significant risk of infection at least during the first year of immunosuppressive treatment. 6, 9, 11, 12, [33] [34] [35] In the few cases in which immunosuppressive treatment had to be further continued, the risk was still present, but at a lower level and in fact only few infectious episodes were observed.
Some considerations could be made analyzing separately the epidemiology of bacteremias and IFI observed in our center. In fact, in a population not receiving any antibacterial prophylaxis, the highest percentage of patients with bacteremia was observed during the first year after Bacteremias and mycoses in allogeneic HSCT E Castagnola et al Table 4 Epidemiology of bacteremias and invasive mycoses during the different periods of immunosuppression after HSCT HSCT, and in particular during the 0-30 day period, and during the 'chronic GvHD' phase (days 101-365). However, if rates were also considered, in the first month after HSCT, high rates corresponded to high percentages, whereas in the 101-365 day period, a low infectious rate corresponded to high percentages. In other words, in both types of transplant, a high number of events should be expected in the short period corresponding to the first month after HSCT, while in the following periods, a high percentage of events could still be observed, but stretched out over a long period of time (that is until the end of the first year). As a practical consequence, antibacterial prophylaxis tailored to local epidemiology might be considered during the days 0-30 period when neutropenia and mucositis are the prominent risk factor. However, this approach, based on a single center observation, has never been evaluated in a double-blind, placebo-controlled multicenter randomized clinical trial in allogeneic HSCT recipients. 36 As for invasive mycoses, we confirmed other experiences both in children and adults, showing that in populations receiving fluconazole prophylaxis and environmental control measures, the burden of invasive mycoses is not high. 17, [37] [38] [39] [40] [41] Therefore, because of a high number needed to treat for a long period to prevent one event, 42 the low incidence of IFI observed in the pediatric population 43 seems not to support the use of antifungal prophylaxis recommended in adults with severe GvHD. 40, 44 We believe that the ideal approach of a randomized controlled clinical trial is very difficult to implement when focusing on the pediatric population in which the event under study is rarer than in adults and the population at risk (that is children with cancer) is fortunately much smaller.
Several studies have already evaluated the epidemiology of bacteremias or invasive mycoses after allogeneic HSCT using different types of descriptive statistics, 5, 7, 8, 10, 12, [33] [34] [35] 45 that, when evaluated separately, do not fully describe the epidemiology of the events. We believe that our approach that considered altogether percentages, cumulative risk and rates allowed a more comprehensive description of the epidemiology of these complications. The estimates we calculated should be taken with caution as derived from a single center study. They should not be used to evaluate the risk of severe infection in a given patient and in a peculiar clinical condition, but to plan management strategies in children receiving allogeneic HSCT. 
